1. Home
  2. Analysis
  3. Gemcitabine
  4. Nitrofurantoin

Gemcitabine and Nitrofurantoin drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among 13 people who take Gemcitabine and Nitrofurantoin. Common interactions include blood sodium decreased among males.

The phase IV clinical study analyzes what interactions people who take Gemcitabine and Nitrofurantoin have. It is created by eHealthMe based on reports from the FDA, and is updated regularly. You may use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 700+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Sep, 26, 2023

13 people who take Gemcitabine and Nitrofurantoin together, and have interactions are studied.

What is Gemcitabine?

Gemcitabine has active ingredients of gemcitabine. Currently, eHealthMe is studying from 27,953 Gemcitabine users.

What is Nitrofurantoin?

Nitrofurantoin has active ingredients of nitrofurantoin, macrocrystalline. It is used in urinary tract infection. Currently, eHealthMe is studying from 4,819 Nitrofurantoin users.

Number of Gemcitabine and Nitrofurantoin reports submitted per year:

Gemcitabine and Nitrofurantoin drug interactions.

Common Gemcitabine and Nitrofurantoin drug interactions by gender *:

female:

n/a

male:

  1. Blood sodium decreased
  2. Haematuria
  3. Hypovolaemia
  4. Nausea
  5. Ovarian cyst
  6. Orthostatic hypotension
  7. Dizziness
  8. Hypotension
  9. Malaise
  10. Autonomic neuropathy

Common Gemcitabine and Nitrofurantoin drug interactions by age *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

n/a

60+:

  1. Blood sodium decreased
  2. Haematuria
  3. Hypovolaemia
  4. Nausea
  5. Ovarian cyst
  6. Orthostatic hypotension
  7. Dizziness
  8. Hypotension
  9. Malaise
  10. Autonomic neuropathy

Common conditions people have *:

  1. Transitional Cell Carcinoma (cancer tumour inner most layer of urinary system): 11 people, 84.62%
  2. Bladder Cancer: 2 people, 15.38%
  3. Breast Cancer: 1 person, 7.69%

* Approximation only. Some reports may have incomplete information.

Do you take Gemcitabine and Nitrofurantoin?

Personalize this study to your gender and age

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related publications that referenced our studies

Related studies

Drug side effects by duration, gender and age:

Common Gemcitabine drug interactions:

Browse interactions between Gemcitabine and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Nitrofurantoin drug interactions:

Browse interactions between Nitrofurantoin and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on gemcitabine and nitrofurantoin, macrocrystalline (the active ingredients of Gemcitabine and Nitrofurantoin, respectively), and Gemcitabine and Nitrofurantoin (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study. Patients in the study may take other drugs besides Gemcitabine and Nitrofurantoin.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 700+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2023 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.